SUNWAY HEALTHCARE

Improving the lives we touch

SUNWAY HEALTHCARE HOLDINGS BERHAD
(Registration No: 202101000296 (1400594-U))

INTERIM FINANCIAL REPORT

FOR THE SECOND QUARTER ENDED 30 JUNE 2026

No.5, Jalan Lagoon Selatan, Bandar Sunway, 47500 Selangor Darul Ehsan, Malaysia
shgir@sunwayhealthcare.com | sunwayhealthcaregroup.com

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2026

		INDIVIDUAL QUARTER			CUMULATIVE QUARTER		
	NOTE	CURRENT YEAR QUARTER UNAUDITED 30/06/2026	PRECEDING YEAR CORRESPONDING QUARTER UNAUDITED 30/06/2025	INCREASE/ (DECREASE)	CURRENT YEAR TO DATE UNAUDITED 30/06/2026	PRECEDING YEAR CORRESPONDING PERIOD UNAUDITED 30/06/2025	INCREASE/ (DECREASE)
		RM'000	RM'000	%	RM'000	RM'000	%
REVENUE		672,899	518,575	30	1,259,944	992,623	27
COST OF SALES		(255,098)	(191,942)	(33)	(480,074)	(360,355)	(33)
GROSS PROFIT		417,801	326,633	28	779,870	632,268	23
OTHER INCOME		16,834	16,138	4	38,390	30,229	27
NET IMPAIRMENT LOSSES ON FINANCIAL ASSETS		(1,906)	(1,772)	(8)	(3,240)	(3,000)	(8)
ADMINISTRATIVE EXPENSES		(251,087)	(206,267)	(22)	(497,127)	(404,045)	(23)
SELLING AND MARKETING EXPENSES		(11,208)	(8,101)	(38)	(22,274)	(13,446)	(66)
OTHER EXPENSES		(71,021)	(63,273)	(12)	(139,860)	(126,268)	(11)
PROFIT FROM OPERATIONS		99,413	63,358	57	155,759	115,738	35
FINANCE INCOME		10,186	10,001	2	14,406	15,888	(9)
FINANCE COSTS		(16,356)	(17,230)	5	(33,013)	(28,507)	(16)
PROFIT BEFORE TAX	B6	93,243	56,129	66	137,152	103,119	33
TAXATION	B5	(15,094)	(14,743)	(2)	(25,671)	(22,981)	(12)
PROFIT FOR THE PERIOD		**78,149**	**41,386**	89	**111,481**	**80,138**	39
ATTRIBUTABLE TO:							
- OWNERS OF THE PARENT		78,156	41,385	89	111,487	80,136	39
- NON-CONTROLLING INTERESTS		(7)	1	>(100)	(6)	2	>(100)
		78,149	**41,386**	89	**111,481**	**80,138**	39
EARNINGS PER SHARE ("EPS")							
- BASIC EPS (sen)	B14	0.68	0.36 [1]	89	0.97	0.70 [1]	39
- DILUTED EPS (sen)	B14	0.68	0.36 [1]	89	0.97	0.70 [1]	39

[1] The basic and diluted earnings per share ("EPS") for the preceding year were calculated based on the Company's enlarged share capital of 11,500,165,558 ordinary shares upon its listing.

(The Unaudited Condensed Consolidated Income Statements should be read in conjunction with the Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 JUNE 2026

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	CURRENT YEAR QUARTER UNAUDITED 30/06/2026	PRECEDING YEAR CORRESPONDING QUARTER UNAUDITED 30/06/2025	CURRENT YEAR TO DATE UNAUDITED 30/06/2026	PRECEDING YEAR CORRESPONDING PERIOD UNAUDITED 30/06/2025
	RM'000	RM'000	RM'000	RM'000
PROFIT FOR THE PERIOD	78,149	41,386	111,481	80,138
OTHER COMPREHENSIVE INCOME/(LOSS) TO BE RECLASSIFIED TO PROFIT OR LOSS IN SUBSEQUENT PERIODS				
FOREIGN CURRENCY TRANSLATION DIFFERENCES FOR FOREIGN OPERATIONS	22	(2)	(19)	(21)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD	22	(2)	(19)	(21)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**78,171**	**41,384**	**111,462**	**80,117**
ATTRIBUTABLE TO:				
- OWNERS OF THE PARENT	78,178	41,383	111,468	80,115
- NON-CONTROLLING INTERESTS	(7)	1	(6)	2
	78,171	**41,384**	**111,462**	**80,117**

(The Unaudited Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 30 JUNE 2026

	NOTE	AS AT END OF CURRENT PERIOD UNAUDITED 30/06/2026	AS AT PRECEDING FINANCIAL PERIOD END AUDITED 31/12/2025
		RM'000	RM'000
ASSETS			
Non-current assets			
Property, plant and equipment		3,727,867	3,676,463
Intangible assets		33,356	33,729
Lease receivables		11,055	13,251
Goodwill		2,349	2,349
Deferred tax assets		51,538	57,247
Other investments		22	22
		3,826,187	**3,783,061**
Current assets			
Inventories		118,501	96,107
Trade receivables	B11	366,035	305,184
Other receivables		123,007	103,612
Lease receivables		2,748	1,209
Derivative financial instruments	B9	81	-
Amounts due from related parties		1,288	3,836
Tax recoverable		5,480	5,213
Cash and bank balances		1,276,814	543,282
		1,893,954	**1,058,443**
TOTAL ASSETS		**5,720,141**	**4,841,504**
EQUITY AND LIABILITIES			
Current liabilities			
Borrowings	B8	517,821	303,304
Trade payables		287,214	285,580
Other payables		297,870	270,690
Amounts due to related parties		60,413	54,218
Derivative financial instruments	B9	1,290	3,653
Lease liabilities		5,387	7,890
Tax payable		19,566	11,136
		1,189,561	**936,471**
Non-current liabilities			
Borrowings	B8	1,087,000	1,287,000
Deferred tax liabilities		76,529	78,439
Lease liabilities		17,833	18,883
		1,181,362	**1,384,322**
Total liabilities		**2,370,923**	**2,320,793**
Equity attributable to Owners of the Parent			
Share capital		2,993,467	2,174,189
Reserves		355,683	346,512
		3,349,150	2,520,701
Non-controlling interests		68	10
Total equity		**3,349,218**	**2,520,711**
TOTAL EQUITY AND LIABILITIES		**5,720,141**	**4,841,504**
Number of ordinary shares ('000)		11,501,455	11,500,166
Net assets per share attributable to Owners of the Parent (RM)		0.29	0.22 *

*Net assets per ordinary share as at 31 December 2025 was calculated based on the Company's enlarged share capital of 11,500,165,558 ordinary shares upon its Listing.

(The Unaudited Condensed Consolidated Statements of Financial Position should be read in conjunction with the Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 JUNE 2026

	I--------------------ATTRIBUTABLE TO OWNERS OF THE PARENT --------------------I							
	I-------------- NON-DISTRIBUTABLE --------------I			DISTRIBUTABLE				
	SHARE CAPITAL RM'000	EXCHANGE TRANSLATION RESERVE RM'000	SHARE OPTION RESERVE RM'000	RETAINED EARNINGS RM'000	TOTAL RESERVES RM'000	TOTAL ATTRIBUTABLE TO OWNERS OF THE PARENT RM'000	NON-CONTROLLING INTERESTS RM'000	TOTAL EQUITY RM'000
PERIOD ENDED 30 JUNE 2026								
At 1 January 2026	**2,174,189**	**(763)**	**-**	**347,275**	**346,512**	**2,520,701**	**10**	**2,520,711**
Profit for the financial period	-	-	-	111,487	111,487	**111,487**	(6)	**111,481**
Other comprehensive loss, net of tax	-	(19)	-	-	(19)	**(19)**	-	**(19)**
Total comprehensive (loss)/income	**-**	**(19)**	**-**	**111,487**	**111,468**	**111,468**	**(6)**	**111,462**
Transaction with owners								
Issuance of ordinary shares pursuant to Initial Public Offering ("IPO")	833,762	-	-	-	-	**833,762**	-	**833,762**
Share issuance costs	(16,598)	-	-	-	-	**(16,598)**	-	**(16,598)**
Issuance of ordinary shares pursuant to Employee Share Options Scheme ("ESOS")	2,114	-	(245)	-	(245)	**1,869**	-	**1,869**
Share option granted under ESOS	-	-	3,187	-	3,187	**3,187**	-	**3,187**
Issuance of ordinary shares by subsidiary to non-controlling interests	-	-	-	-	-	**-**	65	**65**
Dividends paid	-	-	-	(105,239)	(105,239)	**(105,239)**	-	**(105,239)**
Dividends paid to non-controlling interests	-	-	-	-	-	**-**	(1)	**(1)**
Total transactions with owners	819,278	-	2,942	(105,239)	(102,297)	**716,981**	64	**717,045**
At 30 June 2026	**2,993,467**	**(782)**	**2,942**	**353,523**	**355,683**	**3,349,150**	**68**	**3,349,218**
PERIOD ENDED 30 JUNE 2025								
At 1 January 2025	**2,174,189**	**(485)**	**-**	**717,563**	**717,078**	**2,891,267**	**9**	**2,891,276**
						-		
Profit for the financial period	-	-	-	80,136	80,136	**80,136**	2	**80,138**
Other comprehensive loss, net of tax	-	(21)	-	-	(21)	**(21)**	-	**(21)**
Total comprehensive (loss)/income	**-**	**(21)**	**-**	**80,136**	**80,115**	**80,115**	**2**	**80,117**
Transaction with owners								
Dividends paid	-	-	-	(11,250)	(11,250)	**(11,250)**	-	**(11,250)**
Dividends paid to non-controlling interests	-	-	-	-	-	-	(3)	**(3)**
Total transaction with owners	-	-	-	(11,250)	(11,250)	**(11,250)**	(3)	**(11,253)**
At 30 June 2025	**2,174,189**	**(506)**	**-**	**786,449**	**785,943**	**2,960,132**	**8**	**2,960,140**

(The Unaudited Condensed Consolidated Statements of Changes in Equity should be read in conjunction with Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED 30 JUNE 2026

	FOR THE 6 MONTHS PERIOD ENDED UNAUDITED 30/06/2026	FOR THE 6 MONTHS PERIOD ENDED UNAUDITED 30/06/2025
	RM'000	RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	137,152	103,119
Adjustments for:		
Depreciation and amortisation:		
- property, plant and equipment	100,490	80,917
- intangible assets	6,128	5,578
- right-of-use assets	8,421	3,121
Finance income	(14,406)	(15,888)
Interest expenses	33,013	28,507
Net unrealised loss on foreign exchange	2,315	-
(Gain)/ Loss on disposal of property, plant and equipment	(62)	860
Share options expenses	3,187	-
Fair value gain on derivative financial instruments	(3,315)	-
Net impairment losses on:		
- trade receivables	3,240	3,009
Write down of inventories	220	130
Write off:		
- trade receivables	808	1,254
- inventories	179	84
- property, plant and equipment	150	62
Operating profit before working capital changes	277,520	210,753
Changes in working capital		
Inventories	(22,793)	(7,187)
Trade receivables	(64,019)	(24,757)
Other receivables	(18,727)	(13,357)
Amounts due from related parties	2,549	23,909
Trade payables	1,634	20,309
Other payables	10,132	46,231
Amounts due to related parties	(2,982)	(7,130)
Cash generated from operations	183,314	248,771
Tax paid	(20,763)	(22,384)
Tax refunded	7,058	-
Net cash from operating activities	**169,609**	**226,387**

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED 30 JUNE 2026 (CONT'D)

	NOTE	FOR THE 6 MONTHS PERIOD ENDED UNAUDITED 30/06/2026	FOR THE 6 MONTHS PERIOD ENDED UNAUDITED 30/06/2025
		RM'000	RM'000
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from disposal of property, plant & equipment		125	1,242
Acquisition of property, plant and equipment		(136,941)	(348,828)
Acquisition of intangible assets		(2,620)	(2,278)
Interest received		14,406	15,888
Net cash used in investing activities		**(125,030)**	**(333,976)**
CASH FLOWS FROM FINANCING ACTIVITIES			
Drawdowns of borrowings		622,110	1,189,704
Repayments of borrowings		(609,911)	(691,640)
Net proceeds from the issuance of ordinary shares pursuant to the IPO	B15	817,164	-
Proceeds from the issuance of ordinary shares pursuant to the ESOS		1,869	-
Proceeds from issuance of shares by subsidiary to non-controlling interests		65	-
Payments of lease liabilities		(5,056)	(3,322)
Interest paid		(32,052)	(28,098)
Dividends paid		(105,239)	(11,250)
Dividends paid to non-controlling interests of subsidiaries		(1)	(3)
Net cash from financing activities		**688,949**	**455,391**
NET INCREASE IN CASH AND CASH EQUIVALENTS		733,528	347,802
EFFECTS OF EXCHANGE RATE CHANGES		4	(8)
CASH AND CASH EQUIVALENTS AT BEGINNING OF FINANCIAL YEAR		543,282	767,959
CASH AND CASH EQUIVALENTS AT END OF FINANCIAL PERIOD		**1,276,814**	**1,115,753**
Cash at banks and on hand		191,331	231,731
Short term funds			
- Money market funds		1,085,483	884,022
CASH AND CASH EQUIVALENTS		**1,276,814**	**1,115,753**

(The Unaudited Condensed Consolidated Statements of Cash Flows should be read in conjunction with Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

A1. Accounting Policies and Basis of Preparation

The interim financial report is unaudited and has been prepared in accordance with MFRS 134 *Interim Financial Reporting* issued by the Malaysian Accounting Standards Board ("MASB") and Paragraph 9.22 and Appendix 9B of Bursa Malaysia Securities Berhad ("Bursa Securities") Listing Requirements.

The interim financial report should be read in conjunction with the audited financial statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

The accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the annual financial statements for the financial year ended 31 December 2025, except for the adoption of the following Amendments to MFRS and Annual Improvements that became effective on 1 January 2026, as disclosed below:

Title	Effective Date
Amendments to the Classification and Measurement of Financial Instruments (Amendments to MFRS 9 and MFRS 7)	1 January 2026
Annual Improvements to MFRS Accounting Standards - Volume 11	1 January 2026
Contracts Referencing Nature-dependent Electricity (Amendments to MFRS 9 and MFRS 7)	1 January 2026

The adoption of these pronouncements did not have a material impact on the Group's interim financial report for the financial period ended 30 June 2026.

A2. Report of the Auditors

The report of the auditors of preceding annual financial statements was not subject to any qualification.

A3. Seasonal or Cyclical Factors of Operations

The results for the current quarter under review were not materially affected by seasonal or cyclical factors of operations.

A4. Material Unusual Items

There were no material unusual items affecting the amounts reported for the current quarter under review.

A5. Material Changes in Estimates

There were no material changes in estimates of amounts reported in prior financial year that have a material effect on the results for the current financial period under review.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A6. Issuances, Cancellations, Repurchases, Resales and Repayments of Equity Securities

(a) Pursuant to the Company's listing on the Main Market of Bursa Securities (“Listing”), an IPO comprising up to 1,968,996,020 ordinary shares was undertaken and structured as follows:

(i) Public Issue of 575,008,300 new ordinary shares in the Company (“Issue Shares”), involving:
- 230,003,400 Issue Shares made available for application by the Malaysian public, of which 115,001,700 Issue Shares were set aside for application by Bumiputera citizens, companies, cooperatives, societies and institutions;
- 115,001,700 Issue Shares made available to the Directors and eligible employees of the Group, persons who have contributed to the success of the Group, Directors of Sunway Berhad ("Sunway") and eligible employees of Sunway Group;
- 230,003,200 Issue Shares made available for application by institutional and selected investors; and

(ii) Offer for sale of 1,393,987,720 existing shares (“Offer Shares”) made available by way of private placement to Bumiputera investors approved by the Ministry of Investment, Trade and Industry of Malaysia ("MITI"), as well as institutional and selected investors.

The IPO was completed and the Company was listed on the Main Market of Bursa Malaysia Securities Berhad on 18 March 2026 with an enlarged issued share capital of 11,500,165,558 ordinary shares.

(b) During the current financial period, 1,289,000 ordinary shares were issued pursuant to the exercise of employees' share options granted under the Employees Share Option Scheme.

Save as disclosed, there were no other issuances, cancellations, repurchases, resales and repayments of equity securities for the current financial period under review.

A7. Dividends Paid

During the current financial period ended 30 June 2026, the dividends declared and paid by the Company were as follows:

(a) The Company has on 4 February 2026 declared and paid a single-tier interim dividend of 8.24 sen per ordinary share amounting to RM100,000,000 to all members who are registered in the Register of Members as at 3 February 2026 in respect of the financial year ending 31 December 2026.

(b) The Company has on 19 March 2026 declared and paid a single-tier dividend of 0.3 sen per ordinary share amounting to RM5,239,726.03 to Greenwood Capital Pte Ltd in respect of the financial year ending 31 December 2026, pursuant to Clause 10.6 of the Shareholders’ Agreement ("SA") and Clause 4(f) of the 3rd supplemental agreement (“3rd Supplemental SSA”). Sunway City Sdn. Bhd. had waived its entitlement to the distribution of this dividend.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A8. Segmental Reporting

For management purposes, the Group is organised into two (2) reportable segments based on their product and services. The reportable segments are summarised as follows:

(i) Hospital operations - operation of medical centres and provision of medical consultation services.

(ii) Others - investment holding activities, provision of financial services, senior living care and assistance, operation of traditional and complementary medicine centre, provision of nursing care services, provision of ambulatory care services, provision of training services, leasing of properties and other related activities.

Management monitors the operating results of its business units separately for the purposes of resource allocation and performance evaluation. Segment results, assets and liabilities include items that are directly attributable to a segment as well as those that can be allocated on a reasonable and consistent basis. Unallocated items comprise corporate assets, liabilities and expenses.

Segmental results for the financial period ended 30 June 2026 are as follows:

	Hospital operations RM'000	Others RM'000	Eliminations RM'000	Total RM'000
Revenue				
Sales to external customers	1,236,066	23,878	-	1,259,944
Inter-segment revenue	6,157	463	(6,620)	-
Total revenue	**1,242,223**	**24,341**	**(6,620)**	**1,259,944**
Results				
Earnings Before Interest, Taxation, Depreciation and Amortisation ("EBITDA") *	**289,524**	**(18,726)**	**-**	**270,798**
Profit/(loss) from operations	180,205	(24,446)	-	155,759
Finance income	2,606	79,691	(67,891)	14,406
Finance costs	(61,093)	(39,811)	67,891	(33,013)
Profit before tax	121,718	15,434	-	137,152
Taxation	(18,304)	(7,367)	-	(25,671)
Profit for the period	103,414	8,067	-	111,481
Non-controlling interests	-	-	6	6
Attributable to owners of the parent	**103,414**	**8,067**	**6**	**111,487**

	Hospital operations RM'000	Others RM'000	Eliminations RM'000	Total RM'000
OTHER SEGMENT INFORMATION				
Depreciation and amortisation	109,319	5,720	-	115,039
Capital expenditure	156,604	4,649	-	161,253

Segmental assets and liabilities as at 30 June 2026 are as follows:

	Hospital operations RM'000	Others RM'000	Eliminations RM'000	Total RM'000
Assets				
Segment assets	4,203,963	6,153,684	(4,694,524)	5,663,123
Unallocated assets				57,018
Total assets				**5,720,141**
Liabilities				
Segment liabilities	2,988,884	2,148,416	(2,862,472)	2,274,828
Unallocated liabilities				96,095
Total liabilities				**2,370,923**

* EBITDA is calculated as profit/(loss) for the period, plus taxation, finance costs and depreciation and amortisation, less finance income.

A9. Valuation of Property, Plant and Equipment

All items of property, plant and equipment (excluding right-of-use assets) are initially recorded at cost. Subsequent to initial recognition, such assets are carried at cost less any accumulated depreciation and any accumulated impairment losses. There was no revaluation of freehold land and buildings for the current financial period.

A10. Material Events Subsequent to the end of the Reporting Period

On 29 July 2026, Sunway Medical Centre Sdn Bhd ("SMC"), a 99.9%-owned subsidiary of the Company, has entered into a sale and purchase agreement ("SPA") with Sunway Marketplace Sdn Bhd ("Sunway Marketplace"), Sunway Parkview Sdn Bhd ("Sunway Parkview") and Sunway Iskandar Sdn Bhd ("Sunway Iskandar"), in relation to the proposed acquisition of four (4) parcels of freehold lands measuring in aggregate approximately 9.918 acres, all located at Sunway City Iskandar Puteri in Mukim Pulai, Daerah Johor Bahru, Negeri Johor, for a total purchase consideration of RM45.37 million.

SMC and Sunway Marketplace had previously entered into a sale and purchase agreement dated 18 November 2024 ("Existing SPA") for the acquisition of a registered lease over a parcel of freehold land held under H.S.(D) 605673, PTD 200694 as disclosed in the Prospectus of the Company dated 27 February 2026. The Existing SPA has been terminated on even date following the execution of the SPA.

Save as disclosed, there were no other material events subsequent to the end of the reporting period under review that have not been reflected in this interim financial report.

A11. Changes in the Composition of the Group

(a) On 5 June 2026, Sunway Medical 3C4 Sdn. Bhd. ("SM3C4") (formerly known as Sunway Iskandar Medical Centre Sdn Bhd), an indirect subsidiary of Sunway Healthcare Holdings Berhad ("SHH" or the "Company"), completed an allotment of 249,998 new ordinary shares at an issue price of RM1.00 per share for a total cash consideration of RM249,998. Following the allotment, the issued share capital of SM3C4 increased from 2 ordinary shares to 250,000 ordinary shares. Of the 249,998 new ordinary shares issued, 184,998 shares were allotted to SHH and 65,000 shares were allotted to RKRH Sdn. Bhd. As a result, SHH's equity interest in SM3C4 decreased from 100% to 74%. The allotment is not expected to have any material effect on the earnings per share, net assets per share, gearing, issued share capital, or substantial shareholders' shareholdings of SHH for the current financial year.

(b) On 18 June 2026, Sunway Healthcare Ventures Sdn. Bhd. ("SHV"), a wholly-owned subsidiary of the Company, was incorporated in Malaysia with an issued share capital of RM2 comprising 2 ordinary shares. SHV was incorporated to undertake investment holding and such other activities as may be determined by the Company from time to time.

Save as disclosed, there were no other significant changes in the composition of the Group for the current financial period ended 30 June 2026.

A12. Contingent Liabilities and Assets

There were no material changes in contingent liabilities or contingent assets of the Group as at the date of this report.

A13. Commitments

Capital commitments not provided for in the financial period ended 30 June 2026 are as follows:

	30/06/2026 RM'000	31/12/2025 RM'000
Approved and contracted for property, plant and equipment and intangible assets	310,785	309,854
Approved but not contracted for property, plant and equipment and intangible assets	2,094,395	1,979,363
	2,405,180	**2,289,217**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A14. Significant Related Party Transactions

The significant related party transactions set out below were carried out in the normal course of business and on terms and conditions not materially different from those obtainable in transactions with unrelated parties.

	Current Quarter Ended		Cumulative Year To Date	
	30/06/2026	30/06/2025	30/06/2026	30/06/2025
	RM'000	RM'000	RM'000	RM'000
Transactions with Sunway Construction Group Berhad Group				
Provision of construction, building works and services	(59,157)	(25,225)	(66,736)	(57,404)
Sales and provision of medical services	181	1,189	217	1,213
Transactions with Sunway Berhad Group				
Sales and provision of medical services	1,058	1,343	1,812	1,673
Provision of information technology, computer products software support, maintenance and consultancy services	(1,703)	(1,236)	(3,085)	(4,442)
Leasing and rental of premises/ properties	(5,801)	(211)	(6,648)	(461)
Provision of car park management, carpark rental and related services	(823)	(485)	(1,548)	(832)
Provision of hotel accommodation, food & beverage and related services	(1,259)	(298)	(2,725)	(1,135)
Provision of Human Resources administrative services	(904)	(719)	(1,541)	(1,202)
Provision of interior decorations and related services, and renovation works	(1,878)	(9,255)	(2,727)	(9,674)
Provision of management services, trademark license fee and other related services	(2,004)	(1,317)	(3,505)	(1,999)
Provision of project management services	(3,151)	(2,327)	(3,565)	(2,795)

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of Financial Performance

Analysis of performance of the respective operating segments are as follows:

	Individual Quarter ended			Cumulative Quarter ended		
	30/06/2026	30/06/2025	Increase/ (Decrease)	30/06/2026	30/06/2025	Increase/ (Decrease)
	RM'000	RM'000	%	RM'000	RM'000	%
Revenue						
Hospital operations	659,247	510,469	29	1,236,066	976,715	27
Others	13,652	8,106	68	23,878	15,908	50
	672,899	**518,575**	30	**1,259,944**	**992,623**	27
EBITDA						
Hospital operations	163,674	113,035	45	289,524	207,696	39
Others	(4,904)	(1,813)	>(100)	(18,726)	(2,342)	>(100)
	158,770	**111,222**	43	**270,798**	**205,354**	32
Profit Before Tax						
Hospital operations	77,709	44,333	75	121,718	78,863	54
Others	15,534	11,796	32	15,434	24,256	(36)
	93,243	**56,129**	66	**137,152**	**103,119**	33

Quarter ended 30 June 2026 compared with quarter ended 30 June 2025 (“year-on-year" or “y-o-y")

The Group recorded revenue of RM672.9 million and EBITDA of RM158.8 million for the current quarter ended 30 June 2026, compared with revenue of RM518.6 million and EBITDA of RM111.2 million in the corresponding quarter of the previous financial period. Revenue increased by 30% y-o-y, mainly driven by higher contributions from the hospital operations segment. EBITDA increased by 43%, supported by stronger operating performance in the hospital operations segment. Profit before tax rose 66% y-o-y, driven by the higher EBITDA achieved during the quarter, partially offset by increased depreciation expenses arising from the Group's ongoing capacity expansion initiatives.

The hospital operations segment recorded revenue of RM659.2 million in the current quarter, compared with RM510.5 million in the corresponding quarter of the previous financial period, representing an increase of 29%. The growth was mainly attributable to higher patient volumes across the Group's hospitals, as well as increased revenue contributions from Sunway Medical Centre ("SMC") Sunway City, Damansara and Ipoh. Foreign patient revenue increased by 31% to RM84.9 million, from RM65.0 million in the corresponding quarter of the previous financial year. The growth was primarily driven by higher patient inflows from Indonesia, China and Cambodia.

The Group’s overall bed occupancy rate for the current quarter was 73% compared with 67% in the corresponding quarter of the previous financial period. In Q2 2026, inpatient admissions in the hospital operations segment increased by 19% to 32,599, while revenue per inpatient admission grew by 8% to RM12,515. EBITDA growth was supported by stronger operational performance across the hospital operations segment, underpinned by higher patient activity and revenue growth, partially offset by higher operating expenses including staff costs and other non-recurring costs.

Year-to-date ended 30 June 2026 compared with year-to-date ended 30 June 2025

For the six-month period ended 30 June 2026, the Group recorded revenue of RM1,259.9 million and EBITDA of RM270.8 million, compared with revenue of RM992.6 million and EBITDA of RM205.4 million in the corresponding period of the previous year. This represents a 27% y-o-y increase in revenue and a 32% increase in EBITDA. The higher revenue was driven by stronger contributions across all business segments, while the improvement in EBITDA was primarily attributable to stronger operating performance from the hospital operations segment. Profit before tax increased by 33% to RM137.2 million, from RM103.1 million in the corresponding period of the previous year, broadly in line with the increase in EBITDA, partially offset by higher depreciation expenses associated with the Group's capacity expansion.

The hospital operations segment recorded revenue of RM1,236.1 million for the current six-month period ended 30 June 2026, compared with RM976.7 million in the corresponding period of the previous year, representing a 27% increase. The growth was primarily driven by stronger contributions across all hospitals within the Group. Foreign patient revenue increased significantly by 39% to RM171.6 million, compared with RM123.8 million in the corresponding period of the previous year, mainly attributable to higher patient arrivals from Indonesia, China and Cambodia.

The Group's overall bed occupancy rate improved to 70%, compared with 68% in the corresponding period of the previous year. In support of growing patient demand, the Group expanded its total licensed bed capacity from 1,647 beds to 1,855 beds as at 30 June 2026, representing an addition of 208 beds or a 13% y-o-y increase. Inpatient admissions increased by 17% y-o-y to 61,535, while revenue per inpatient admission rose by 9% to RM12,488, reflecting higher inpatient volumes and improved case mix. Accordingly, EBITDA growth was supported by stronger operational performance across the hospital operations segment, partially offset by higher operating expenses, including staff costs and other non-recurring expenses.

B2. Material Changes in the Quarterly Results

Analysis of performance of the respective operating segments are as follows:

	Quarter ended		
	30/06/2026 RM'000	**31/03/2026 RM'000**	**Increase/ (Decrease) %**
Revenue			
Hospital operations	659,247	576,819	14
Others	13,652	10,226	34
	672,899	**587,045**	15
EBITDA			
Hospital operations	163,674	125,850	30
Others	(4,904)	(13,822)	65
	158,770	**112,028**	42
Profit Before Tax			
Hospital operations	77,709	44,009	77
Others	15,534	(100)	>100
	93,243	**43,909**	>100

Quarter ended 30 June 2026 compared with preceding quarter ended 31 March 2026 (“quarter-on-quarter" or “q-o-q")

For the current quarter, the Group recorded revenue of RM672.9 million and EBITDA of RM158.8 million, compared with revenue of RM587.0 million and EBITDA of RM112.0 million in the preceding quarter. This represents a 15% q-o-q increase in revenue and a 42% q-o-q increase in EBITDA. The stronger financial performance was primarily attributable to a recovery in hospital activities following the seasonal impact of festive holidays in the preceding quarter. Profit before tax increased to RM93.2 million in the current quarter from RM43.9 million in the preceding quarter, more than doubling in line with the significant improvement in EBITDA.

The hospital operations segment recorded revenue of RM659.2 million during the current quarter, compared with RM576.8 million in the preceding quarter, representing a 14% q-o-q increase. The growth was driven by improved operational performance and patient activity levels following the festive holiday period in the preceding quarter. Foreign patient revenue declined marginally by 2% to RM84.9 million, compared with RM86.6 million in the preceding quarter. The Group's overall bed occupancy rate improved to 73% in the current quarter from 68% in the preceding quarter. During the quarter, the Group's total licensed bed capacity increased from 1,805 beds as at 31 March 2026 to 1,855 beds as at 30 June 2026, representing an addition of 50 beds or a 3% q-o-q increase. Inpatient admissions increased by 13% to 32,599, while revenue per inpatient admission remained stable at RM12,515. Consequently, EBITDA for the hospital operations segment increased q-o-q, supported by higher revenue and increased patient volumes, partially offset by higher operating expenses, including staff costs and other non-recurring expenses.

B3. Prospects

The second quarter of 2026 ("Q2FY2026") strengthened the Group’s performance for the six-month ended 30 June 2026, supported by broad-based growth across the hospital network, improved operating leverage and rising contributions from the newer hospitals. With patient demand supporting activity and expanded capacity being progressively absorbed, the Group enters the second half of 2026 with stronger earnings momentum and a more balanced contribution across its portfolio.

As at 30 June 2026, the Group had 1,855 licensed beds and a further 217 completed beds available for licensing, bringing total capacity to 2,072 beds. Subsequent to the quarter-end, the completion of SMC Sunway City Tower F increased total capacity to 2,271 beds. The Group continues to make progress on its next phase of brownfield expansion at SMC Penang and SMC Damansara, with preparatory activities advancing in support of their respective development programmes. In senior living, demand at Sunway Sanctuary continues to build, with the Group planning to activate its Phase 2 capacity expansion in 2027 to accommodate further growth. Together with the progressive licensing and operationalisation of completed capacity, these initiatives are expected to increase total bed capacity to approximately 2,400 beds by 2028. The Group will continue to advance its brownfield and greenfield expansion plans, supported by its strong financial position following the listing.

In parallel, the Group continues to progress its planned greenfield hospitals in Seremban Sentral, Iskandar Puteri and Putrajaya. These developments form part of the Group’s longer-term strategy to expand its geographical reach and increase the combined capacity of its hospital network to more than 3,400 beds by 2032, subject to the relevant approvals and prevailing project timelines.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B3. Prospects (Contd.)

The MediAsas pilot, scheduled to run from end-July to October 2026 in the Klang Valley, is expected to provide a more affordable base medical insurance option and support an orderly transition towards a more sustainable medical insurance ecosystem. The Group will continue preparing for the planned MediAsas rollout and the phased implementation of the Diagnosis-Related Group payment framework, while engaging insurers and takaful operators on sustainable reimbursement arrangements.

While geopolitical developments may continue to create volatility in regional travel, freight and input costs, underlying demand for private healthcare and medical tourism remains constructive. The Group will continue to broaden its foreign patient source markets, referral channels and payor partnerships, while maintaining diversified sourcing, adequate inventory buffers and disciplined cost management.

Supported by favourable long-term healthcare demographics, Malaysia's established position as a regional medical tourism destination and the Group's expanding capacity and clinical capabilities, the Group remains positive about its prospects for FY2026. The Group will continue to focus on converting patient-volume growth and capacity activation into sustainable earnings while preserving accessibility, clinical excellence, operational resilience and financial discipline.

B4. Variance of Actual Profit from Profit Forecast

The Company did not issue any profit forecast or profit guarantee during the current year under review.

B5. Taxation

	Individual Quarter		Cumulative Quarter	
	Current Quarter 30/06/2026 RM'000	Preceding Year Corresponding Quarter 30/06/2025 RM'000	Current Year To Date 30/06/2026 RM'000	Preceding Year Corresponding Period 30/06/2025 RM'000
Current taxation	(10,592)	(13,776)	(21,867)	(23,868)
Deferred taxation	(4,502)	(967)	(3,804)	887
	(15,094)	**(14,743)**	**(25,671)**	**(22,981)**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B6. Profit before Tax

The following amounts have been included in arriving at profit before tax:

	Current Quarter 30/06/2026 RM'000	Cumulative Year To Date 30/06/2026 RM'000
Interest income	10,186	14,406
Interest expenses	(16,356)	(33,013)
Net (impairment losses)/reversal of impairment on:		
- Trade receivables	(1,980)	(3,240)
- Other receivables	76	-
- Amounts due from related parties	(2)	-
Share options expenses	(2,352)	(3,187)
Depreciation and amortisation	(59,357)	(115,039)
Net gain on disposal of property, plant and equipment	11	62
Fair value (loss)/gain on derivative financial instruments	(2,623)	3,315
Net unrealised foreign exchange gains/(losses)	3,638	(2,315)
Write down of inventories	(57)	(220)
Written off:-		
- Property, plant and equipment	(87)	(150)
- Inventories	(149)	(179)
- Trade Receivables	(570)	(808)

B7. Status of Corporate Proposal Announced

(a) On 18 November 2024, Sunway Medical Centre Sdn Bhd ("SMC") entered into a sale and purchase agreement with Sunway Marketplace Sdn Bhd for the acquisition of a registered lease over a parcel of land measuring approximately 5.45 acres in Sunway City Iskandar Puteri for the development of Sunway Medical Centre Iskandar Puteri ("Existing SPA"). Subsequently, on 29 July 2026, SMC entered into a sale and purchase agreement with Sunway Marketplace Sdn Bhd, Sunway Parkview Sdn Bhd and Sunway Iskandar Sdn Bhd to acquire four parcels of freehold land measuring approximately 9.918 acres for a total cash consideration of RM45.37 million ("SPA"). The Existing SPA has been terminated on 29 July 2026 following the execution of the SPA. The acquisition replaces the earlier proposed lease acquisition and secures a larger land area within Sunway City Iskandar Puteri, providing greater flexibility for the development and future expansion of Sunway Medical Centre Iskandar Puteri, a proposed 410-bed tertiary hospital.

(b) On 28 October 2025, Sunway Medical Centre Penang Sdn. Bhd. (as purchaser) entered into a sale and purchase agreement with RHB Trustees Berhad (as trustee of Sunway REIT) (as vendor) for the acquisition of all that piece of leasehold land held under Pajakan Negeri No. Hakmilik 2602, Lot 5785, Mukim 01, Daerah Seberang Perai Tengah, Negeri Pulau Pinang measuring approximately 4,294 square metres ("Land") together with the hotel building known as "Sunway Hotel Seberang Jaya" erected on the Land, together with all other structures thereon ("Hotel") and all fixtures, fittings, equipment and tangible property in respect of the Hotel, for a total cash consideration of RM60.00 million. The sale and purchase transaction is pending completion as the parties are in the midst of fulfilling the conditions precedent set out in the said sale and purchase agreement.

(c) On 24 December 2025, Sunway Medical 3C4 Sdn. Bhd. (formerly known as Sunway Iskandar Medical Centre Sdn Bhd) (as purchaser) entered into a sale and purchase agreement with Sunway Integrated Properties Sdn. Bhd. (as vendor) for the acquisition of all the parcels of property comprising the lower 12 of the 22 floors (i.e. from ground floor until 10th floor, including one mezzanine floor comprising two intermediate levels known as levels 1A and 1B) of Tower A of Sunway Medical Centre Velocity, measuring an aggregate of approximately 24,858 square metres in area, for a total cash consideration of RM228.50 million. The sale and purchase transaction is pending completion as the parties are in the midst of fulfilling the conditions precedent set out in the said sale and purchase agreement.

(d) On 23 April 2025, Sunway Healthcare Holdings Berhad ("SHH") entered into a Heads of Agreement ("HOA") with Putrajaya Holdings Sdn Bhd ("PjH") for the joint development of Sunway Medical Centre Putrajaya. On 22 July 2026, SHH and PjH entered into a second Supplemental Heads of Agreement to further extend the HOA term from 22 July 2026 to 30 September 2026, providing additional time to negotiate and finalise the definitive agreements for the proposed joint venture. Sunway Medical Centre Putrajaya is planned as a multi-specialty tertiary hospital with an estimated capacity of 325 beds. The hospital will be located in Precinct 7, Putrajaya, Malaysia's administrative capital, adjacent to Putrajaya Sentral.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B7. Status of Corporate Proposal Announced (Contd.)

(e) On 20 May 2026, SMC has accepted a Letter of Offer dated 4 May 2026 ("Letter of Offer") from Sunway Sentral Seremban Sdn Bhd (formerly known as Sunway Bukit Gambier Sdn Bhd), a related party, in relation to the proposed acquisition of a parcel of freehold land measuring approximately 2.1 acres ("Subject Land"), forming part of a parcel of freehold land held under H.S.(D) 278178, P.T. 10433, Bandar Seremban, Daerah Seremban, Negeri Sembilan, for a total purchase consideration of RM10.79 million. The Letter of Offer to SMC shall form the basis of negotiation and preparation of the Sale and Purchase Agreement, which is to be executed within two (2) months from 20 May 2026, or such later date as may be mutually agreed by the parties in writing.

Other than the above, there were no other corporate proposals pending completion as at the date of this interim financial report.

B8. Group Borrowings and Debt Securities

The Group's borrowings as at 30 June 2026 are as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured borrowing			
Medium term notes	-	387,000	387,000
Total secured borrowing	**-**	**387,000**	**387,000**
Unsecured borrowings			
Receivables financing	181,560	-	181,560
Medium term notes	200,000	700,000	900,000
Banker's acceptances	75,218	-	75,218
Revolving credit	61,043	-	61,043
Total unsecured borrowings	**517,821**	**700,000**	**1,217,821**
Total borrowings	**517,821**	**1,087,000**	**1,604,821**

Included in the Group's borrowings as at 30 June 2026 are amounts denominated in currency profile as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured			
Ringgit Malaysia ("RM")	-	387,000	387,000
Unsecured			
Ringgit Malaysia ("RM")	335,218	700,000	1,035,218
United States Dollar ("USD")	182,603	-	182,603
Total borrowings	**517,821**	**1,087,000**	**1,604,821**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B8. Group Borrowings and Debt Securities (Contd.)

The Group's borrowings as at 31 December 2025 were as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured borrowing			
Medium term notes	-	387,000	387,000
Total secured borrowing	**-**	**387,000**	**387,000**
Unsecured borrowings			
Receivables financing	177,722	-	177,722
Medium term notes	-	900,000	900,000
Banker's acceptances	64,707	-	64,707
Revolving credit	60,875	-	60,875
Total unsecured borrowings	**303,304**	**900,000**	**1,203,304**
Total borrowings	**303,304**	**1,287,000**	**1,590,304**

Included in the Group borrowings as at 31 December 2025 are amounts denominated in currency profile as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured			
Ringgit Malaysia ("RM")	-	387,000	387,000
Unsecured			
Ringgit Malaysia ("RM")	124,707	900,000	1,024,707
United States Dollar ("USD")	178,597	-	178,597
Total borrowings	**303,304**	**1,287,000**	**1,590,304**

Overall, the total borrowings of the Group have increased by RM14.5 million, from RM1,590.3 million as at 31 December 2025 to RM1,604.8 million as at 30 June 2026.

	30/06/2026 %	31/12/2025 %
Weighted average interest rate of borrowings	4.08	4.00
Fixed rate instruments	56%	57%
Floating rate instruments	44%	43%
Total	**100%**	**100%**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B9. Financial Instruments - Derivatives

The Group's derivatives as at 30 June 2026 are as follows:

Type of Derivatives	Contract/ Notional Value RM'000	Net Fair Value RM'000	Gain for the period RM'000
Foreign currency forward contracts			
- Less than 1 year	183,721	(1,209)	3,315
Total derivatives	**183,721**	**(1,209) ***	**3,315**

** Fair value derivative assets of RM81,000 were offset against fair value derivative liabilities of RM1,290,000, resulting in a net fair value liability position of RM1,209,000.*

Foreign currency forward contracts

The Group has entered into foreign currency forward contracts to hedge the foreign exchange exposure arising from its USD-denominated borrowings. The forward contracts are undertaken on a back-to-back basis with the scheduled repayment dates of the underlying borrowings, thereby mitigating the Group's exposure to fluctuations in the USD/MYR exchange rate. As these contracts are not designated in hedge accounting relationships under MFRS 9 Financial Instruments, all fair value movements are recognised in profit or loss.

As at 30 June 2026, the Group had outstanding foreign currency forward contracts with a total notional value of RM183.7 million. These contracts were in a net fair value liability position of RM1.2 million and generated a fair value gain of RM3.3 million during the financial period. These fair value movements arose from the mark-to-market revaluation of the outstanding forward contracts at the reporting date following changes in USD/MYR exchange rates and forward pricing.

The derivatives are classified as Level 2 fair value measurements within the fair value hierarchy prescribed under MFRS 13 Fair Value Measurement. There were no transfers between Level 1, Level 2 and Level 3 fair value measurements during the financial period.

B10. Fair Value Changes of Financial Liabilities

As at 30 June 2026, the Group does not have any financial liabilities measured at Fair Value through Profit or Loss ("FVTPL").

B11. Aging Analysis of Trade Receivables

The aging analysis of the Group's trade receivables are as follows:

	30/06/2026 RM'000	**31/12/2025 RM'000**
Current	268,115	212,211
1 to 30 days past due	38,266	36,451
31 to 60 days past due	20,525	19,781
61 to 90 days past due	14,340	10,995
More than 90 days past due	24,789	25,746
Total trade receivables	366,035	305,184

B12. Changes in Material Litigation

There were no material litigation by or against the Group as at 30 June 2026.

B13. Dividends

Other than the dividends paid as disclosed in note A7, no dividend has been proposed by the Board of Directors for the financial period ended 30 June 2026.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B14. Earnings per Share

The profit used as the numerator in calculating basic and diluted earnings per share for the quarter and financial period is as follows:

	Individual Quarter		Cumulative Quarter	
	Current Quarter 30/06/2026 RM'000	Preceding Year Corresponding Quarter 30/06/2025 RM'000	Current Year To Date 30/06/2026 RM'000	Preceding Year Corresponding Period 30/06/2025 RM'000
Basic earnings per share				
Profit attributable to owners of the parent	78,156	41,385	111,487	80,136
Weighted average number of ordinary shares ('000)	11,500,180	11,500,166	11,500,173	11,500,166
Earnings per share (Basic) (sen)	0.68	0.36 [1]	0.97	0.70 [1]
Diluted earnings per share				
Profit attributable to owners of the parent	78,156	41,385	111,487	80,136
Weighted average number of ordinary shares ('000)	11,511,496	11,500,166	11,507,135	11,500,166
Earnings per share (Diluted) (sen)	0.68	0.36 [1]	0.97	0.70 [1]

[1] For the purpose of EPS (Basic) computation, the weighted average number of ordinary shares in issue for corresponding periods presented in based on the enlarged issued share capital of 11,500,165,558 ordinary shares upon the Listing, in order to provide a consistent and comparable basis across periods.

B15. Utilisation of Proceeds from the Public Issue

The gross proceeds raised by the Group from the Public Issue of RM833.8 million shall be utilised in the following manner:

Utilisation of proceeds	Proposed utilisation RM'000	Proposed utilisation %	Actual utilisation RM'000	Balance to be utilised RM'000	Timeframe for utilisation
Capital expenditure for expansion of existing hospitals	554,050	66.5%	(35,921)	518,129	Within 36 months
Redemption of Sukuk Wakalah	249,712	29.9%	-	249,712	Within 24 months
Defray fees and expenses in relation to the IPO and Listing	30,000	3.6%	(30,000) *	-	Within 3 months
	833,762	100.0%	(65,921)	767,841	

* Includes RM16.6 million which has been capitalised as share issuance costs and recognised in the Statements of Changes in Equity.

By Order of the Board

Tan Kim Aun (MAICSA 7002988)
Lee Poh Yean (MAICSA 7015043)

Secretaries

20 August 2026